# Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

> **NCT00325429** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 150 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT00325429
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 150 (—)
- **Last updated:** 2009-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325429, "Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00325429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*